Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients.
| Autor: | Garbuzenko DV; Department of Faculty Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia. garb@inbox.ru. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of hepatology [World J Hepatol] 2024 Feb 27; Vol. 16 (2), pp. 126-134. |
| DOI: | 10.4254/wjh.v16.i2.126 |
| Abstrakt: | This editorial describes the contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis (LC) patients according to the current guidelines. Gastroesophageal variceal bleeding is the most dangerous complication of portal hypertension in LC patients. Risk stratification and determination of an individual approach to the choice of therapeutic measures aimed at their prevention and management has emerged as one of the top concerns in modern hepatology. According to the current guidelines, in the absence of clinically significant portal hypertension, etiological and non-etiological therapies of LC is advisable for the primary preventing gastroesophageal variceal bleeding, whereas its presence serves as an indication for the administration of non-selective β-blockers, among which carvedilol is the drug of choice. Non-selective β-blockers, as well as endoscopic variceal ligation and transjugular intrahepatic portosystemic shunt can be used to prevent recurrence of gastroesophageal variceal bleeding. Pharmacotherapy with vasoactive drugs (terlipressin, somatostatin, octreotide), endoscopic variceal ligation, endovascular techniques and transjugular intrahepatic portosystemic shunt are recommended for the treatment of acute gastroesophageal variceal bleeding. Objective and accurate risk stratification of gastroesophageal variceal bleeding will allow developing individual strategies for their prevention and management, avoiding the first and further decompensation in LC, which will improve the prognosis and survival of patients suffering from it. Competing Interests: Conflict-of-interest statement: Author have no conflict of interest to declare. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|